□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □ □ □□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □ □ □ □ □ □□□ □ □ □ □ □ □□ □ □□□□ □ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□Guest Professor Yuuya KASAHARA 1）人工核酸を高効率に導入可能な改変ポリメラーゼの開発2）核酸医薬品創出へ向けた新規スクリーニング手法の開拓3）Aptamer Based Drug Design (ABDD) 創薬プラットフォームの構築4）細胞内移行性人工核酸アプタマーの創出072-641-9882 招へい教授 笠原 勇矢 y-kasahara@nibiohn.go.jp招へい教授 笠原 勇矢Oligonucleotide Properties. Molecules 2023, 28, 7911.1. Kuroda M, Kasahara Y, Hirose M, Yamaguma H, Oda M, Nagao C, Mizuguchi K. Construction of a Tm-value prediction model and molecular dynamics study of AmNA-containing gapmer antisense oligonucleotide. Mol. Ther. Nucleic Acids 2024, 35, 102272.2. Kohashi H, Nagata R, Tamenori Y, Amatani T, Ueda Y, Mori Y, Kasahara Y, Obika S, Shimojo M. A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides. Nucleic Acids Res. 2024, 52, 4784–4798.3. Hoshino H, Kasahara Y, Obika S. Polyamines promote xenobiotic nucleic acid synthesis by modified thermophilic polymerase mutants. RSC Chem. Biol. 2024, 5, 467–472.4. Huo W, Miki K, Mu H, Osawa T, Yamaguma H, Kasahara Y, Obika S, Kawaguchi Y, Hirose H, Futaki S, Miyazaki Y, Shinoda W, Akai S, Ohe K. Light-controllable cell-membrane disturbance for intracellular delivery. J. Mater. Chem. B 2024, 12, 4138–4147.5. □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□6. Yoshida T, Morihiro K, Naito Y, Mikami A, Kasahara Y, Inoue T, Obika S. Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides. Nucleic Acids Res□□□□□□□□□□□□□□□□□□□□□□7. Hoshino H, Kasahara Y, Kuwahara M, Obika S. DNA polymerase variants with high processivity and accuracy for encoding and decoding locked nucleic acid sequences. J. Am. Chem. Soc□□□□□□□□□□□□□□□□□□□□□□□□□8. □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□antisense oligonucleotide, Mol. Ther. Nucleic Acids□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□XNA Screening and Design
元のページ ../index.html#42